ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 171 filers reported holding ASCENDIS PHARMA A/S in Q4 2021. The put-call ratio across all filers is 1.59 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,695 | +2.0% | 18,097 | -2.8% | 0.18% | -39.1% |
| Q2 2023 | $1,661 | -17.1% | 18,612 | -0.4% | 0.30% | +9.8% |
| Q1 2023 | $2,003 | -6.6% | 18,678 | +6.4% | 0.28% | -15.4% |
| Q4 2022 | $2,144 | -99.9% | 17,553 | -14.1% | 0.32% | +1.6% |
| Q3 2022 | $2,109,000 | +28.8% | 20,429 | +16.0% | 0.32% | +9.6% |
| Q2 2022 | $1,637,000 | -25.9% | 17,605 | -6.5% | 0.29% | -19.3% |
| Q1 2022 | $2,209,000 | -21.0% | 18,820 | -9.5% | 0.36% | -24.1% |
| Q4 2021 | $2,797,000 | -27.4% | 20,792 | -14.0% | 0.48% | +2.1% |
| Q3 2021 | $3,853,000 | +61.1% | 24,172 | +33.0% | 0.47% | +68.6% |
| Q2 2021 | $2,392,000 | -12.5% | 18,180 | -14.3% | 0.28% | -42.7% |
| Q1 2021 | $2,734,000 | -35.2% | 21,210 | -16.2% | 0.48% | -5.7% |
| Q4 2020 | $4,222,000 | -27.7% | 25,314 | -56.5% | 0.51% | -42.9% |
| Q3 2020 | $5,839,000 | +19.0% | 58,242 | +75.6% | 0.90% | +1.7% |
| Q2 2020 | $4,905,000 | – | 33,161 | – | 0.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RA Capital Management | 5,865,338 | $978,221,000 | 13.68% |
| Vivo Capital, LLC | 1,797,745 | $299,828,000 | 13.38% |
| Sofinnova Investments, Inc. | 1,109,874 | $185,105,000 | 11.02% |
| Avoro Capital Advisors LLC | 1,800,000 | $300,204,000 | 5.17% |
| Eventide Asset Management | 1,704,148 | $284,218,000 | 4.36% |
| Stenahm Asset Managment Ltd | 29,000 | $4,837,000 | 4.07% |
| Ghost Tree Capital, LLC | 105,000 | $17,512,000 | 3.90% |
| Eversept Partners, LP | 187,043 | $31,195,032 | 3.66% |
| Spyglass Capital Management LLC | 701,594 | $117,012,000 | 3.59% |
| Q Global Advisors, LLC | 23,183 | $3,866,000 | 2.72% |